Apoptosis Intervention in Cell and Organ Preservation

描述(申请人提供)：BioLife Solutions Inc.成立于 1998年3月，专门为 人体细胞、组织和器官的低温和冷冻保存。这个 该公司的研究人员部分由分子生物学家组成，他们拥有 积累的证据支持这样一个概念，即 制定未来的保存解决方案是了解分子细胞 在保存保存过程中触发的死亡连锁效应。生物生命 已开发出HypolhermosolR(HTS)低温和 基于这种分子生物学设计的冷冻保存液 这是一种独特的策略，专为细胞特定应用而配制。《生物生命》 成功完成本文所述的第一阶段工作后， 将HTS出售给几家企业、学术和政府集团。Bio Life拥有 被选中与Vitagen公司和迈阿密糖尿病大学合作 研究机构(DRI)开发两种特殊的HTS配方 运输/储存Vitagen的体外肝脏辅助装置(HTS-ELAD)和 DRI‘s可移植胰岛(HTS-Islets)。《生物生命》提出三点建议 第二阶段SBIR的研究主题。首先，生物生命将继续其基本的 保存诱导细胞的分子机制研究 死亡。这项基础研究计划在文物保护行业中是独一无二的 并为DRI采用HTS进行人胰岛移植做出了贡献。 其次，BioLife将在HTS中添加凋亡和坏死性抑制剂 通过文献鉴定以及合成维生素E类似物 通过组合化学，使HTS-ELAD和HTS-胰岛可以 最优化。最后，第二阶段项目最具挑战性的主题是 开发一种高通量蛋白质芯片检测系统，将成为 生物生命第三阶段添加剂发现计划的基石。这反过来又会 允许公司通过利用微阵列进行快速检测 技术，以便将来可以开发更多的i-its变体 客户。 建议的商业应用： 不可用

DESCRIPTION (provided by applicant): BioLife Solutions Inc. was incorporated in March, 1998, and specializes in developing solutions and procedures for the hypothermic and cryopreservation of human cells, tissues and organs. The Company's research staff is composed, in part, of molecular biologists who have accumulated evidence supportive of the concept that the best manner in which to formulate future preservation solutions is to understand the molecular cell death cascades that are triggered during preservation storage regimes. BioLife has developed the HypolhermosolR (HTS) family of hypothermic and cryopreservative solutions that is designed based on this molecular biology strategy and is uniquely formulated for cell-specific applications. BioLife's successful completion of the Phase I work described herein has resulted in the sale of HTS to several corporate, academic, and government groups. BioLife has selected to work with Vitagen Corporation and the University of Miami Diabetes Research Institute (DRI) to develop two special HTS formulations for the shipping/storing of Vitagen's Extracorporeal Liver Assist Device (HTS-ELAD) and DRI's transplantable pancreatic islets (HTS-ISLETS). BioLife proposes three research themes in this Phase II SBIR. First, BioLife will continue its basic research on the molecular mechanisms underlying preservation-induced cell death. This basic research initiative is unique in the preservation industry and contributed to DRI's adoption of HTS for human islet transplantation. Second, BioLife will modify HTS with apoptotic and necrotic inhibitors identified through the literature as well as Vitamin E analogues synthesized through combinatorial chemistry so that HTS-ELAD and HTS-ISLETS can be optimized. Finally, the most challenging theme of the Phase II project is to develop a ProteinChip microarray high throughput assay system that will be the keystone of BioLife's Phase III additive discovery program. This, in turn, will allow the company to perform rapid assays by harnessing the microarrav technology so that additional I-ITS variants can be developed for future clients. PROPOSED COMMERCIAL APPLICATION: Not Available